clinical development

QPS Miami Research Associates Publish on Corn (Maize) Therapy for Mild Depression or Anxiety

Douglas S. Kalman, Samantha Feldman, Rafael Rivas Vazquez and Diane R. Krieger of Miami Research Associates published the results of a pilot clinical trial assessing the anti-depressive effects of a chemical derived from corn. In addition, they compared the outcome to the effects of S-adenosyl-methionine (SAM-e).

For the trial, subjects with mild depression or anxiety were randomized to eight weeks of supplementation with either UP165, a chemical derived from Zea mays L., or SAM-e. To evaluate efficacy, the Beck Depression Inventory second edition (BDI-II), the Beck Anxiety Inventory (BAI), and the Schwartz Outcome Scale (SOS-10) were administered at weeks 0, 4 and 8. Those receiving UP165 achieved significant depression reduction comparable to those receiving SAM-e. Kalman et al. concluded that UP165 may be beneficial as a nutritional psychotropic intervention for mood enhancement in those with mild depression or anxiety, and that randomized placebo comparator trials appear warranted.

20 years in pharma R&D navigation